6 recruiting, 4 completed, 1 terminated. 6 Phase 1, 4 Phase 2, 1 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 3, Recruiting 2, Terminated 1 |
| Phase 2 | 4 | Completed 2, Recruiting 2 |
| Early Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Azenosertib: new trials by email Literature Review of Azenosertib trials Research Report on Azenosertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression Investigator's choice of Chemotherapy, Azenosertib - Ovarian Cancer | Phase 3 | Recruiting | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 420 | 2026-04-17 | 2026-08-12 |
| Azenosertib in Uterine Serous Carcinoma: Biomarker Study Azenosertib - Uterine Serous Carcinoma, Uterine Carcinoma | Phase 2 | Recruiting | Joyce Liu, MD | 25 | 2025-03-05 | 2026-03-02 |
| Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors Azenosertib, Biopsy Procedure, Biospecimen Collection - Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 48 | 2025-02-03 | 2026-10-27 |
| ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC Azenosertib, Carboplatin, Pembrolizumab - Breast Cancer, Breast Cancer Female | Phase 1 | Terminated | Filipa Lynce, MD | 7 | 2024-05-01 | 2026-06-04 |
| A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer azenosertib - High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Phase 2 | Recruiting | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 310 | 2022-02-17 | 2026-09-29 |
| A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer Azenosertib, Niraparib - Ovarian Cancer, Platinum-resistant Ovarian Cancer | Phase 1 / Phase 2 | Completed | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 117 | 2022-01-27 | 2026-03-18 |
| A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma Azenosertib, Gemcitabine - Osteosarcoma | Phase 1 | Completed | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 31 | 2021-08-01 | 2026-04-03 |
| A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma Azenosertib - Uterine Serous Carcinoma | Phase 2 | Completed | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 92 | 2021-07-28 | 2026-03-18 |
| A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer Azenosertib, Carboplatin, Pegylated liposomal doxorubicin - Solid Tumor, Epithelial Ovarian Cancer | Phase 1 | Recruiting | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 172 | 2020-10-26 | 2026-04-07 |
| A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors Azenosertib - Solid Tumor | Phase 1 | Completed | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 274 | 2019-11-01 | 2026-03-18 |
| Targeted Pathway Inhibition in Patients With Pancreatic Cancer Cobimetinib, Olaparib, Onvansertib - Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | Early Phase 1 | Recruiting | OHSU Knight Cancer Institute | 90 | 2019-08-01 | 2026-09-04 |
Ovarian Neoplasms (3) · Fallopian Tube Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Ovarian Epithelial (1) · Cystadenocarcinoma, Serous (1) · Neoplasm Metastasis (1) · Osteosarcoma (1) · Pancreatic Neoplasms (1) · Stomach Neoplasms (1) · Triple Negative Breast Neoplasms (1) · Uterine Neoplasms (1)
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc (7) · Filipa Lynce, MD (1) · Joyce Liu, MD (1) · National Cancer Institute (NCI) (1) · OHSU Knight Cancer Institute (1)
United States (11) · Australia (4) · France (4) · South Korea (3) · Belgium (2) · Canada (2) · Georgia (2) · Italy (2) · Poland (2) · Spain (2) · Bosnia and Herzegovina (1) · Bulgaria (1) · Germany (1) · Ireland (1) · Serbia (1)
Charles D Lopez (1) · Filipa Lynce, MD (1) · Funda Meric-Bernstam (1) · Joyce Liu, MD, MPH (1)
UM1CA186688 (1)